CCM
PRQR icon

Cribstone Capital Management’s ProQR Therapeutics PRQR Stock Holding History

Cribstone Capital Management’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-286
Closed -$1K – 733
2017
Q1 		$1K Hold
286
– – ﹤0.01% 722
2016
Q4 		$1K Sell
286
-714
-71% -$3.68K ﹤0.01% 676
2016
Q3 		$6K Buy
+1,000
New +$5.5K ﹤0.01% 570

Other funds holding PRQR

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AGA
Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return

Cribstone Capital Management's PRQR Position: Q2 2017 in Review

Cribstone Capital Management sold out of ProQR Therapeutics (PRQR) in Q2 2017, closing a stake of 286 shares — an estimated $1K sold.

Cribstone Capital Management first reported a position in PRQR in Q3 2016 and held it in 3 quarters. The position peaked at $6K in Q3 2016. 18 funds tracked by Wall St. Rank hold PRQR as of Q2 2017.

  • Cribstone Capital Management reported no remaining ProQR Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Cribstone Capital Management sold 286 ProQR Therapeutics shares in Q2 2017, an estimated $1K.
  • Cribstone Capital Management first reported a position in ProQR Therapeutics in Q3 2016 and held it in 3 quarters.
  • Cribstone Capital Management's ProQR Therapeutics position peaked at $6K in Q3 2016.
  • 18 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2017.

Based on Cribstone Capital Management's 13F filing for Q2 2017, filed 18 Jul 2017.